Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment

Liver International

Volumn 35, Issue 8, 2015, Pages 2001-2008

  Negri, Francesca V ^a   Dal Bello, Barbara ^b   Porta, Camillo ^b   Campanini, Nicoletta ^a   Rossi, Sandro ^b   Tinelli, Carmine ^b   Poggi, Guido ^c   Missale, Gabriele ^a   Fanello, Silvia ^d   Salvagni, Stefania ^a   Ardizzoni, Andrea ^a   Maria, Silini Enrico ^a,e  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c Electrophisiology and Cardiac Pacing Unit Istituto di Cura Città di Pavia   (Italy)

^d S MARIA NUOVA HOSPITAL   (Italy)

^e UNIVERSITY OF PARMA   (Italy)

Author keywords

Hepatocellular carcinoma; pERK expression; Sorafenib; VEGFR 2 expression

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; GLUTAMATE AMMONIA LIGASE; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PROTEIN KINASE B; SORAFENIB; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; EIF2AK3 PROTEIN, HUMAN; NICOTINAMIDE; PROTEIN KINASE R; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RESISTANCE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BLOOD; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; DISEASE FREE SURVIVAL; DRUG RESISTANCE; KAPLAN MEIER METHOD; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SURVIVAL ANALYSIS; TUMOR INVASION;

AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; EIF-2 KINASE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84937973752     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12778     Document Type: Article

References (41)

1. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-87.
2. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 1997; 236: 54-s8.
3. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29: 4989-5005.
4. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-44.
5. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
6. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
7. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-300.
8. Llovet JM, Peña CE, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18: 2290-300.
9. Boyault S, Rickman DS, de Reyniès A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007; 45: 42-52.
10. Chiang DY, Villanueva A, Hoshida Y, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008; 68: 6779-88.
11. Dal Bello B, Rosa L, Campanini N, et al. Glutamine synthetase immunostaining correlates with pathologic features of hepatocellular carcinoma and better survival after radiofrequency thermal ablation. Clin Cancer Res 2010; 16: 2157-66.
12. Lachenmayer A, Alsinet C, Savic R, et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 2012; 18: 4997-4507.
13. Semela D, Piguet AC, Kolev M, et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 2007; 46: 840-8.
14. Piguet AC, Saar B, Hlushchuk R, et al. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther 2011; 10: 1007-17.
15. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109.
16. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006; 98: 326-34.
17. Cheng A, Kang Y, Lin D, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013; 31: 4067-75.
18. Rimassa L, Pressiani T, Boni C, et al. A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma. Oncologist 2013; 18: 379-80.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
20. Audard V, Grimber G, Elie C, et al. Cholestasis is a marker for hepatocellular carcinomas displaying β-catenin mutations. J Pathol 2007; 212: 345-52.
21. Chadha KS, Khoury T, Yu J, et al. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol 2006; 13: 933-9.
22. Chen D, Zhao P, Li SQ, et al. Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib. Eur J Surg Oncol 2013; 39: 974-80.
23. Decaussin M, Sartelet H, Robert C, et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 1999; 188: 369-77.
24. Malik SN, Brattain M, Ghosh PM, et al. Immunohistochemical demonstration of phopho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002; 8: 1168-71.
25. Henderson-Jackson EB, Helm J, Ghayouri M, et al. Correlation between Mcl-1 and pAKT protein expression in colorectal cancer. Int J Clin Exp Pathol 2010; 3: 768-74.
26. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26: 3291-310.
27. Zhang Z, Zhou X, Shen H, Wang D, Wang Y. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med 2009; 7: 41.
28. Personeni N, Rimassa L, Pressiani T, et al. Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2013; 139: 1179-87.
29. Schmitz KJ, Wohlschlaeger J, Lang H, et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 2008; 48: 83-90.
30. Rudalska R, Dauch D, Longerich T, et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med 2014; 20: 1138-46.
31. Ito Y, Sasaki Y, Horimoto M, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 1998; 27: 951-8.
32. Cervello M, Bachvarov D, Lampiasi N, et al. Cell Cycle 2012; 11: 2843-55.
33. Ebos JML, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-9.
34. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-31.
35. Brahimi-Horn MC, Chiche J, Pouysségur J. Hypoxia and cancer. J Mol Med 2007; 85: 1301-7.
36. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001; 61: 6624-8.
37. Scartozzi M, Faloppi L, Svegliati Baroni G, et al. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer 2014; 135: 1247-56.
38. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000; 37: 443-8.
39. Al-Habboubi HH, Mahdi N, Abu-Hijleh TM, et al. The relation of vascular endothelial growth factor (VEGF) gene polymorphisms on VEGF levels and the risk of vasoocclusive crisis in sickle cell disease. Eur J Haematol 2012; 89: 403-9.
40. Horwitz E, Stein I, Andreozzi M, et al. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Cancer Discov 2014; 4: 730-43.
41. Hoshida Y, Toffanin S, Lachenmayer A, et al. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010; 30: 35-51.